Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLGA + PEI + pPD-L1 + pDKK-1
- Development stage
- Preclinical
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Gene Therapies
- Administration
- Subcutaneous
01
Overview
This is a combination nanovaccine technology for cancer immunotherapy, designed for DNA vaccine delivery. It combines poly(lactic-co-glycolic acid) (PLGA) and polyethylenimine (PEI) as nanoparticle carriers co-loaded with two plasmid DNAs encoding programmed death-ligand 1 (pPD-L1) and Dickkopf-1 (pDKK-1). PLGA provides biocompatibility and controlled release, while PEI facilitates gene delivery via endosomal escape. The vaccine aims to induce robust antitumor immune responses by enhancing CD8+ T cell activation—DKK-1 acts as a tumor antigen and pPD-L1 enables immune checkpoint blockade—resulting in increased immunogenicity and tumor growth inhibition. This combination has been studied primarily for multiple myeloma and other hematologic malignancies in preclinical settings[1][4].
- Other names
- PLGA/PEI-pPD-L1/pDKK-1PLGA/PEI-pPD-L1/pDDK-1
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)LRP5 (Low-density lipoprotein receptor-related protein 5)CD274 (Programmed cell death protein 1 ligand 1)DKK1 (Dickkopf-related protein 1)
Beyond the preview
Go deeper on PLGA + PEI + pPD-L1 + pDKK-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLGA + PEI + pPD-L1 + pDKK-1.